Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6249755 | 0.84 | TAAR1 (0.57) | TAAR1HRH3MEN1ALDH1A1TP53 | |
| SCHEMBL29204036 | 0.82 | TAAR1 (0.55) | TAAR1HRH3 | |
| SCHEMBL20081762 | 0.82 | TAAR1 (0.55) | TAAR1HRH3MEN1ALDH1A1TP53 | |
| SCHEMBL25430010 | 0.82 | TAAR1 (0.55) | TAAR1HRH3MEN1ALDH1A1TP53 | |
| SCHEMBL11955566 | 0.81 | TAAR1 (0.53) | TAAR1HRH3MEN1ALDH1A1TP53 | |
| SCHEMBL8508740 | 0.80 | CYP1A2 (0.57) | TAAR1ALDH1A1CYP1A2HTR7AOC3 | |
| SCHEMBL11947342 | 0.80 | TAAR1 (0.52) | TAAR1HRH3MEN1ALDH1A1TP53 | |
| SCHEMBL16105820 | 0.79 | DAO (0.55) | TAAR1ALDH1A1DAOHTT | |
| SCHEMBL23972532 | 0.78 | HRH3 (0.50) | TAAR1HRH3ALDH1A1HTR7HTT | |
| SCHEMBL18762839 | 0.77 | HRH3 (0.84) | TAAR1HRH3MEN1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | TAAR1 1183/4885HRH3 2291/4885MEN1 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.